Neglected and Underrepresented Subpopulations: Elderly and Performance Status 2 Patients with Advanced-Stage Non-Small-Cell Lung Cancer

This publication has 39 references indexed in Scilit:

• O-104 XYOTAXT™ vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The STELLAR 4 Phase III study
  Lung Cancer, 2005
• O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study
  Lung Cancer, 2005
• Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma
  Cancer, 2004
• Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
  Journal of Clinical Oncology, 2003
• Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
  Journal of Clinical Oncology, 2003
• O-52 ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC
  Lung Cancer, 2003
• Long-term trends in cancer mortality in the United States, 1930-1998
  Cancer, 2003
• Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
  New England Journal of Medicine, 1999
• Age and Clinical Decision Making in Oncology Patients
  JNCI Journal of the National Cancer Institute, 1994
• Chemotherapy for Metastatic Non-Small-Cell Lung Cancer -- Can That Dog Hunt?
  JNCI Journal of the National Cancer Institute, 1993